Advertisement

SilverSky LifeSciences DxPx Conference 2019 Düsseldorf Medica 600x60px
Document › Details

Eurofins. (7/15/15). "Press Release: Eurofins Reinforces Its Footprint in Japan with the Acquisition of Nihon Soken".

Region Region Japan
Organisations Organisation Eurofins Scientific SE (EUFI.PA)
  Group Eurofins (Group)
  Organisation 2 Nihon Soken
  Group Eurofins (Group)
Products Product environmental analysis
  Product 2 analytical services
Index term Index term Nihon Soken–Eurofins: investment, 201507 acquisition by Eurofins
Persons Person Martin, Gilles G. (Eurofins 200701 CEO + founder)
  Person 2 Oishi, Kazuyoshi (Nihon Soken 201507 CEO)
     


Eurofins Scientific (EUFI.PA), the world leader in environment testing services, announces that it has signed an agreement to acquire Nihon Soken in Japan. The transaction is expected to close by the end of July.

Founded in 1971, Nihon Soken is one of the country's leading environmental testing service providers with a strong focus in pollution analysis, and is the largest laboratory serving the Fukushima prefecture. Nihon Soken employs 112 staff, and expects to generate revenues of almost EUR 10m in 2015, with EBITDA margin broadly in-line with Eurofins' objective.

The acquisition provides the Group market leadership in radioactive surface measurement testing in Fukushima, and reinforces Eurofins' Radioactive Material Analysis (RMA) capabilities in Japan. Nihon Soken should allow the Group to further leverage its state-of-the-art high throughput laboratory for RMA in Tokyo, as well as its global network of RMA laboratories in China, France and Germany. In addition, Nihon Soken's expertise in remediation and monitoring is a strong addition to the Group's existing competencies.

Comment from Mr. Kazuyoshi Oishi, Nihon Soken President and CEO: "It is a great honor to become part of the Eurofins global group of companies. As one of the oldest environment testing companies in Japan, Nihon Soken is committed to global environment protection, and to further developing its competencies within the Eurofins Group and its footprint in the region."

Comment from Dr. Gilles Martin, Eurofins CEO: "Nihon Soken is an excellent strategic fit to Eurofins' existing activities in Japan, and reinforces the Group's growing presence in the Asia Pacific region. Furthermore, this acquisition provides the Group an opportunity to play a more active role in the country's remediation and long-term recovery efforts following the tragic Fukushima nuclear accident in 2011, by leveraging Eurofins' full laboratory network capabilities."


For more information about Eurofins, please visit www.eurofins.com or contact:

Investor Relations
Eurofins Scientific Group
Phone: +32 2 766 1620
E-mail: ir@eurofins.com


Notes for the editor:

Eurofins - a global leader in bio-analysis

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services.

With over 17,000 staff in more than 200 laboratories across 36 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).


Important disclaimer: This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.

   
Record changed: 2019-06-09

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 600x60px

More documents for Eurofins (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 600x60px




» top